Charles Cosby Reed

US Patent:

20020150177, Oct 17, 2002

Filed:

Apr 13, 2001

Appl. No.:

09/835030

Inventors:

Charles Reed - Yardley PA, US

Assignee:

SARNOFF CORPORATION

International Classification:

H04L027/22
H04L027/16
H04L027/14
H03D003/18
H03D003/24
H04L007/00
H04L025/00
H04L025/40

US Classification:

375/326000, 375/327000, 375/371000, 375/373000, 375/376000

Abstract:

Method and apparatus for performing joint timing recovery in a digital receiver using multiple input signals. The apparatus comprises a plurality of phase detectors, a summer, a level shifter, a loop filter and a numerically controlled oscillator NCO. The phase detectors produce a phase signal by comparing a timing signal produced by the NCO with the input signals. The phase signals are then summed and the level shifter adjusts the summed value to compensate for the number of signals used to form the sum, i.e., the summed value is adjusted to be within the input range of the NCO.

US Patent:

20200239906, Jul 30, 2020

Filed:

Jan 9, 2020

Appl. No.:

16/738015

Inventors:

- Blacksburg VA, US
Charles C. Reed - Souderton PA, US
Brandon Cuthbertson - Newland CT, US
Sunil Chada - Missouri City TX, US
William E. Fogler - Rockville MD, US

International Classification:

C12N 15/85
C12N 15/86
C07K 14/54
C12N 15/861
A61K 38/19
A61K 38/20
A61K 38/21
A61K 38/44
A61K 48/00
C12N 5/0784

Abstract:

This invention relates to the field of therapeutics. Most specifically, the invention provides methods of generating conditionally expressing vectors for one or more immunomodulators under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals. These vector may be provided to treat a variety of disorders, e.g., neoplastic disorders, through direct injection or through in vitro engineered cells, such as dendritic cells.

US Patent:

20190031770, Jan 31, 2019

Filed:

Oct 11, 2018

Appl. No.:

16/158053

Inventors:

- Blacksburg VA, US
Charles REED - Souderton PA, US

International Classification:

C07K 16/32
C07K 16/00

Abstract:

Single chain antibody polypeptides with engineered peptide bond crossovers in the light chain and/or heavy chain variable domains, compositions comprising the same, and methods of making and using the same are provided. The antibody polypeptides can be intercalated (crossover) single chain variable fragments (scFvs) or any antibody frameworks which comprise such scFvs, such as diabodies, bispecific antibodies or bssFvs. The single chain antibody polypeptides may or may not contain a linker. The single chain antibody polypeptides are useful in applications where standard (conventional) scFvs are useful, such as in the development of scFv libraries for screening, as therapeutic antibodies, or in in vitro and in vivo targeting applications.

US Patent:

20180344876, Dec 6, 2018

Filed:

May 31, 2018

Appl. No.:

15/993773

Inventors:

- Blacksburg VA, US
Charles C. REED - Souderton PA, US
Brandon CUTHERTSON - Newland NC, US
Sunil CHADA - Missouri City TX, US
William E. FOGLER - Rockville MD, US
Fayaz KHAZI - Frederick MD, US

Assignee:

Intrexon Corporation - Blacksburg VA

International Classification:

A61K 48/00
C07K 14/705
A61K 38/20
A61K 38/21
C07K 14/47
C07K 14/505
C07K 14/54
C12N 15/86
C12N 15/85
A61K 38/18
C07K 14/565
C07K 14/56

Abstract:

This invention relates to the field of therapeutics. Disclosed are methods of generating conditionally expressing erythropoietin under the control of an ecdysone receptor-based gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals. The methods of the invention cause an in vivo increase in the expression of erythropoietin and an increase in the hematocrit or volume percentage of red blood cells in blood after administration of the ligand.

US Patent:

20180002719, Jan 4, 2018

Filed:

Jul 13, 2017

Appl. No.:

15/648623

Inventors:

- Blacksburg VA, US
Charles C. Reed - Souderton PA, US
Brandon Cuthbertson - Newland CT, US
Sunil Chada - Missouri TX, US
William E. Fogler - Rockville MD, US

Assignee:

Intrexon Corporation - Blacksburg VA

International Classification:

C12N 15/85
A61K 38/20
A61K 38/21
A61K 38/44
C12N 15/86
A61K 38/19
C07K 14/54
A61K 48/00
C12N 5/0784
C12N 15/861

Abstract:

This invention relates to the field of therapeutics. Most specifically, the invention provides methods of generating conditionally expressing vectors for one or more immuunomodulators under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals. These vector may be provided to treat a variety of disorders, e.g., neoplastic disorders, through direct injection or through in vitro engineered cells, such as dendritic cells.

US Patent:

20170291934, Oct 12, 2017

Filed:

Sep 21, 2015

Appl. No.:

15/511956

Inventors:

Charles C. REED - Souderton PA, US
Gregory Ian FROST - Palm Beach FL, US
Joan Mazzarelli SOPCZYNSKI - Oreland PA, US
Chi ZHANG - Omaha NE, US
- BLACKSBURG VA, US

International Classification:

C07K 14/54
G01N 33/567
G01N 33/50
A61K 45/00
C12P 21/02

Abstract:

The present invention relates to modified forms of IL-12. These modified forms of IL-12 may be engineered to have a shortened in vivo half-life compared and/or enhanced localization of biological effects compared to that of corresponding non-modified form of IL-12. Short half-life and membrane bound forms of IL-12 may provide greater therapeutic control for in vivo therapeutic delivery, in particular when used in combination with ligand inducible delivery of IL-12. Modified forms of IL-12 engineered to have shortened in vivo half-life and/or enhanced localization of biological effects include heterodimeric p35/p40, single chain and membrane bound forms of IL-12 wherein a naturally occurring IL-12 amino acid sequence is genetically modified to enhance susceptibility of the IL-12 molecule to in vivo proteolytic degradation.

US Patent:

20160317678, Nov 3, 2016

Filed:

May 11, 2016

Appl. No.:

15/151947

Inventors:

- Blacksburg VA, US
Charles C. Reed - Souderton PA, US
Brandon Cuthbertson - Newland NC, US
Sunil Chada - Missouri City TX, US
William E. Fogler - Rockville MD, US
Fayaz Khazi - Frederick MD, US

International Classification:

A61K 48/00
C12N 15/86
A61K 38/18
C12N 15/85
A61K 38/20
A61K 38/21

Abstract:

This invention relates to the field of therapeutics. Disclosed are methods of generating conditionally expressing erythropoietin under the control of an ecdysone receptor-based gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals. The methods of the invention cause an in vivo increase in the expression of erythropoietin and an increase in the hematocrit or volume percentage of red blood cells in blood after administration of the ligand.

US Patent:

20160208285, Jul 21, 2016

Filed:

Dec 29, 2015

Appl. No.:

14/982815

Inventors:

- Blacksburg VA, US
Charles C. Reed - Souderton PA, US
Brandon Cuthbertson - Newland CT, US
Sunil Chada - Missouri City TX, US
William E. Fogler - Rockville MD, US

International Classification:

C12N 15/85
A61K 38/20
A61K 48/00
C12N 5/0784
A61K 38/19

Abstract:

This invention relates to the field of therapeutics. Most specifically, the invention provides methods of generating conditionally expressing vectors for one or more immunomodulators under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals. These vector may be provided to treat a variety of disorders, e.g., neoplastic disorders, through direct injection or through in vitro engineered cells, such as dendritic cells.